Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date March 19, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,429 |
Reported balance
After 2026-03-19 transaction · row 1
1 source rowRow 1 · 2026-03-19 · Tax withholding · Disposed 931 · Balance 92,429 F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2023 Filed Aug 16, 2023 20:46 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 104 | $12.38 | $1,287.52 |
DisclosureSEC source: 0001628280-23-029681 · wk-form4_1692218782.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,879 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 22:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 462 | $19.50 | $9,009.00 |
DisclosureSEC source: 0001628280-23-025783 · wk-form4_1690409329.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,983 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 07-17-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 337 | $23.21 | $7,821.77 |
DisclosureSEC source: 0001437749-23-016543 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,445 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 15, 2023 Filed May 18, 2023 01:52 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 72 | $18.71 | $1,347.12 |
DisclosureSEC source: 0001437749-23-015003 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,782 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 23:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 292 | $19.33 | $5,644.36 |
DisclosureSEC source: 0001437749-23-010841 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,059 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 7/17/2020 Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 23:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 739 | $20.03 | $14,802.17 |
DisclosureSEC source: 0001437749-23-009874 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,351 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 06, 2023 Filed May 17, 2023 01:47 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 739 | $20.03 | $14,802.17 |
DisclosureSEC source: 0001437749-23-014860 · rdgdoc.xml · nonDerivative · entry 2 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,146 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. F3 · balance_after: This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 2,795 shares. Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:47 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 2,795 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-014860 · rdgdoc.xml · derivative · entry 3 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · derivative.expiration_date: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 31, 2023 Filed May 17, 2023 01:47 UTC Amendment | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 2,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-014860 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,022 | $22.75 | $23,250.50 |
DisclosureSEC source: 0001437749-23-005440 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,090 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 09, 2023 Filed Feb 14, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 55 | $24.60 | $1,353.00 |
DisclosureSEC source: 0001437749-23-003204 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,112 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 19, 2023 Filed Jan 21, 2023 00:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 374 | $22.93 | $8,575.82 |
DisclosureSEC source: 0001437749-23-001487 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,167 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 12,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000821 · rdgdoc.xml · derivative · entry 2 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,450 Underlying: Common Stock · 12,450 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| January 03, 2023 Filed Jan 11, 2023 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 12,450 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-000821 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,541 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 38 | $23.16 | $880.08 |
DisclosureSEC source: 0001437749-22-027395 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,091 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 272 | $21.76 | $5,918.72 |
DisclosureSEC source: 0001437749-22-025239 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,129 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 40 | $23.17 | $926.80 |
DisclosureSEC source: 0001437749-22-020213 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,401 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 22, 2022 Filed Jul 27, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleComon Stock | 252 | $17.85 | $4,498.20 |
DisclosureSEC source: 0001437749-22-017814 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,441 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 13, 2022 Filed May 18, 2022 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 40 | $12.32 | $492.80 |
DisclosureSEC source: 0001437749-22-012849 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,693 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 21, 2022 Filed Apr 23, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 325 | $13.94 | $4,530.50 |
DisclosureSEC source: 0001437749-22-009565 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,733 F1 · kind: The sale reported herein was made by a broker to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:20 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 14,019 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-005772 · rdgdoc.xml · derivative · entry 2 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,019 Underlying: Common Stock · 14,019 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:20 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 14,019 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-005772 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,058 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 197 | $29.38 | $5,787.86 |
DisclosureSEC source: 0001437749-22-003345 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,039 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 20, 2022 Filed Jan 25, 2022 02:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 332 | $30.24 | $10,039.68 |
DisclosureSEC source: 0001437749-22-001524 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,236 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 20, 2021 Filed Oct 23, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 272 | $42.34 | $11,516.48 |
DisclosureSEC source: 0001437749-21-024187 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,568 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 20, 2021 Filed Jul 23, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,059 | $45.10 | $47,760.90 |
DisclosureSEC source: 0001437749-21-017394 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,840 F1 · shares: The sales reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 2,795 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003516 · rdgdoc.xml · derivative · entry 2 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,795 Underlying: Common Stock · 2,795 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 2,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003516 · rdgdoc.xml · nonDerivative · entry 1 Aebersold Sarah · CIK 0001837756 · VP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,899 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.